Skip to main content

Genetic carrier screening offers critical insight for patients considering conception or who are early in pregnancy

pregnancy and fertility patient materials image

Genetic carrier screening can provide a better understanding of the likelihood and potential impact of inherited genetic disorders. ACOG recommends that all individuals, regardless of race or ethnicity, be offered screening for the same set of conditions.1 At Quest Diagnostics, we recognize that your patients have questions, and we can provide you with the answers.

QHerit® carrier screening

Broad portfolio of clinically relevant, right-sized solutions for patients

Advances in next-generation sequencing (NGS) have led to expanded carrier screening, making it easier to screen for a greater number of conditions as patients navigate their family planning journey. Our innovative QHerit® product portfolio provides several clinically relevant, right-sized panels designed with American College of Obstetricians and Gynecologists (ACOG) guidelines and American College of Medical Genetics and Genomics (ACMG) Practice Resources in mind.

Learn more about our pan-ethnic carrier screening panels that can provide medically appropriate insights you and your patients need to plan their futures.


Spinal muscular atrophy with silent carrier screening


Spinal muscular atrophy with silent carrier screening
 

  • Early screening is recommended by leading medical organizations
  • 1 in 50 people in the US are carriers3
  • Even if a couple already has healthy children and no family history of SMA, 1 or both parents may still be a carrier
  • Carriers generally do not show signs and symptoms of SMA, but could be at risk to have a child affected with the condition
Learn more about Quest SMA screening

CFvantage® Cystic Fibrosis Expanded Screen

Cystic fibrosis (CF) is an inherited disorder that causes severe damage to the lungs, digestive system, and other organs in the body. The CFvantage® Cystic Fibrosis Expanded Screen from Quest analyzes an expanded number of variants that have been proven to cause cystic fibrosis.4 This panel includes the 23 variants recommended by leading health organizations for screening of all women of childbearing age.1,4 Test code 92068

  • Guidelines recommend that patients with a personal or family history of CF be offered screening
  • If your patient tests positive for 1 CF mutation, guidelines recommend performing a CF screen on the male partner4
  • If he is also a CF carrier, the fetus has a 25% risk of being affected with CF. Guidelines recommend offering the couple genetic counseling and prenatal testing if both partners are CF carriers
  • If your patient’s male partner’s result is negative, his residual risk to be a CF carrier is reduced, and the risk that the fetus is affected with CF is also reduced. The percent risk reduction is based on ethnicity, because the CF screen sensitivity varies by ethnic group

For patients suspected of having CF, additional genetic testing may be considered to determine whether a second rare mutation, not detected by the standard CF screen, is present.


Genomic science specialists are available to help with test selection and results interpretation.

Call 1.866.GENE.INFO (1.866.436.3463)


Laboratory Screening Corresponding Quest Test TEST CODE
Pan-ethnic carrier screening tests

QHerit® carrier screening

5 testing options—up to 611 diseases —empower you to select the medically appropriate panel
View available QHerit panels

 
Prenatal carrier Prenatal Carrier Panel (CFvantage, Fragile X, SMA)a
93349
Cystic fibrosis CFvantage® Cystic Fibrosis Expanded Screen
161 CF variants, including the 23 common variants recommended by ACOG/ACMG
92068
Fragile X XSense®, Fragile X with Reflex 16313
Spinal muscular atrophy SMA Carrier Screen 18041

aPanel components for males do not include specified X-linked diseases.


Test codes may vary by location. Please contact your local laboratory for more information.
 

​References:

  1. The American College of Obstetricians and Gynecologists (ACOG). ACOG committee opinion no. 690: carrier screening in the age of genomic medicine. Obstet Gynecol. 2017;129(3):e35-e40. doi:10.1097/AOG.000000000000195
  2. ObG Project. Spinal muscular atrophy: genetic concepts and carrier screening. Accessed February 19, 2025. https://www.obgproject.com/2017/04/18/spinal-muscular-atrophy-genetic-concepts-carrier-screening
  3. SMA Foundation. About SMA: frequently asked questions. Accessed February 19, 2025. https://smafoundation.org/about-sma/faq
  4. ACOG. ACOG committee opinion no. 486: update on carrier screening for cystic fibrosis. Obstet Gynecol. 2011;117(4):1028-1031. doi:10.1097/AOG.0b013e31821922c2

Genetic carrier screening

QHerit®, our innovative genetic carrier screening portfolio provides clinically relevant, right-sized panels that deliver information that you and your patients need to help plan their futures.

Click to learn more

New podcast: The importance of early screening for SMA

Listen to Lisa Blazejewski, CGC, a genomic science specialist at Quest Diagnostics, talk about the complexity of the SMN1 gene in detecting silent carriers in a podcast from Contemporary OB/GYN.

Click to learn more

Genetic consultation available

Genomic science specialists are available to help with test selection and results interpretation 1.866.GENE.INFO (1.866.436.3463)

Contact us

Contact us to receive additional information on our lab tests, services, and coverage

Contact us